Scientific Posters & Presentations

 ISIET’s International Conference on Inner Ear Therapies – April 2025

• Sensorion’s Symposium Presentation

ARO (Association for Research in Otolaryngology) – January 2025

• Poster N°SA82. Preclinical development of an Adeno Associated Vector Based Gene Therapy (SENS-501) for the Autosomal Recessive Non Syndromic Deafness 9 (DFNB9)
• Poster: GJB2-GT, a Novel AAV-Based Gene Therapy as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A)

ESGCT (European Society of Gene and Cell Therapy) – October 2024

• Poster N°0273 – GJB2 gene therapy-response of two pre-clinical mouse models of the most frequent form of human deafness, DFNB1
  
• Poster N°0051 – Characterization of a safe and functional GT-GJB2 vector for the treatment of DFNB1A hearing loss
  
• Poster N°0052 – Preclinical development of GT-GJB2 as a treatment for the autosomal recessive non-syndromic deafness 1A (DFNB1A) using an adeno associated vector-based gene therapy
  

WCA (World Congress of Audiology) – September 2024

• Replay of the symposium “Are we at the Dawn of a Hearing Loss Revolution?“

IEB (Inner Ear Biology Workshop) – September 2024

• Poster – Multiplexed TMT-based quantitative proteomics identified essential players involved in the mechanism of action of SENS-401 observed under normal or ototoxic conditions in intact cochlear organ cultures

ARO (Association for Research in Otolaryngology) – January 2024

• Poster Su56 – Preclinical Development of SENS-501 as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9) Using an Adeno Associated Vector-Based Gene Therapy”
• Poster Su57 – Surgical Approach for a Safe Intra-Cochlear Injection of AAVs in Macaca Fascicularis
• Poster Su61 – Early Players Involved in Both Cisplatin-Induced Ototoxicity and SENS-401 Protection in Intact Organ Cultures” 
• Presentation – SENS-501 Gene Therapy for Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9)
• Presentation – Assessment of an Adeno Associated Vector-Based Gene Therapy (GJB2-GT) for the Non-Syndromic Deafness 1 (DFNB1) in Cynomolgus Monkeys

KOL webinar on POC Phase 2a study of SENS-401 to prevent residual hearing loss after cochlear implantation – July 5, 2023

• KOL Webinar Presentation Deck (powerpoint)
• KOL Webinar Replay

ASGCT American Society of Gene & Cell Therapy – 2023

• An Integrated Adeno-Associated Vector Development Platform for Inner Ear Disorders
• Preclinical development of an Adeno Associated Vector-Based Gene Therapy (SENS-501) for the Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9)

Sensorion Gene Therapy R&D Day, April 6, 2023
Hearing Institute (Institut Pasteur)

• R&D Day Presentation Deck (Powerpoint)
• R&D Day Replay